Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q4G0X9

UPID:
CCD40_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q4G0X9; A8MTD2; C9JTI9; C9JTJ0; C9JXW1; J3QSY2; Q6PE47; Q9HCD2; Q9NWL5

BACKGROUND:
The Coiled-coil domain-containing protein 40 is integral to the formation and function of cilia and flagella, impacting cellular motility. By facilitating the assembly of key dynein complexes, it ensures the dynamic performance of these cellular structures. Its interaction with CCDC39 is critical for maintaining the 96 nm repeat structure essential for ciliary and flagellar function.

THERAPEUTIC SIGNIFICANCE:
The therapeutic significance of Coiled-coil domain-containing protein 40 is underscored by its involvement in primary ciliary dyskinesia, a disorder affecting motile cilia. Targeting the molecular mechanisms underpinning this protein's function could unlock new avenues for treating respiratory and fertility issues associated with the disease, highlighting the potential of precision medicine in addressing genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.